



Ref: FOIA Reference 2018/19-595

Royal Stoke University Hospital
Quality, Safety and Compliance Department
Newcastle Road
Stoke-on-Trent
Staffordshire
ST4 6QG

Date: 7th February 2019

Email FOI@uhnm.nhs.uk

Dear

I am writing in response to your email dated 11th January 2019 requesting information under the Freedom of Information Act (2000) regarding paediatric asthma.

I can neither confirm nor deny whether the information you have requested is held by the Trust in its entirety. This is because the information requested in questions 1, 2 and 3 is not held centrally, but may be recorded in individual health records. In order to confirm whether this information is held we would therefore have to individually access all health records within the Trust and extract the information where it is present. We therefore estimate that complying with your request is exempt under section 12 of the FOI Act: *cost of compliance is excessive*. The section 12 exemption applies when it is estimated a request will take in excess of 18 hours to complete. We estimate that accessing and reviewing all health records and then extracting relevant information would take longer than the 18 hours allowed for.

Under section 16 of the FOI Act we are required to provide requestors with advice and assistance where possible. We would therefore like to advise you that if your request is shortened to just the questions that we are able to comply within the 18 hour time frame. In order to avoid delay to your response we have provided this below

On 14th January 2019 we contacted you via email as we required clarification on your request. We asked:

Q1, what "drug" are you referring to?

Q2 and Q3 are the questions related to patients having received a drug treatment? If so what?

On 22nd January 2019 you replied via email the following:

"Drugs for treatment Asthma for question 1, 2 and 3"

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 In your Trust, in the past 3 months [latest 3 months available], how many asthma patients aged 18 and over have been treated [with a drug]?

A1 Section 12 exemption as detailed above.

Q2 How many paediatric asthma treated patients [aged 6-17] have been treated in the last 3 months?

A2 As answer 1. Please note that this is based on your clarification “*Drugs for treatment Asthma for question 1, 2 and 3*”

Q3 How many severe asthmatic patients [BTS guidelines, step 4 or 5] have been treated in the last 3 months?

A3 As answer 1.

Q4 How many patients have been treated in the last 3 months with?

- **Omalizumab [Xolair]**
- **Mepolizumab [Nucala]**
- **Reslizumab [Cinqaero]**
- **Benralizumab [Fasenra]**
- **Other [Please state]**

A4 We are unable to provide some of the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers. Please see below:

- Omalizumab = 60 patients in last 3 complete months (Oct-Dec 18)
- Mepoliumab = less than 5 patients in last 3 complete months (Oct-Dec 18)
- Reslizumab = not presently used at UHNM
- Benralizumab = not presently used at UHNM

Q5 How many paediatric patients have treated in the last 3 months with Xolair/omalizumab?

A5 Six paediatric patients have treated in the last 3 months with Xolair/omalizumab

Q6 Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs?

- **Ocreotide**
- **Lanreotide**
- **Pasireotide**
- **Pegvisomant**

A6 Please see below:

- Ocreotide = 93 (plus 1% of the value cannot be assigned to patient numbers as stock on wards issues)
- Lanreotide = 39
- Pasireotide = 0
- Pegvisomant = 0

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 676474.

Yours,



Leah Carlisle
Deputy Head of Quality, Safety & Compliance